Neoadjuvante chemotherapie for muscle-invasive bladder cancer (urothelial carcinoma) in the Netherlands Neoadjuvant chemotherapy and radical surgery improves the survival of patients suffering from muscle-invasive bladder cancer (urothelial carcinoma). The survival benefit in the long term is, however, limited and the chemotherapeutic regimen is toxic. Therefore, clinicians are reluctant to embed neoadjuvant chemotherapy as a treatment modality for muscle-invasive bladder cancer. In the present study, the use of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the Netherlands was assessed by a nationwide survey. In total, 70% responded and neoadjuvant chemotherapy was considered by 25% of the Dutch respondents. In less than 10%, neoadjuvant chemotherapy was actually started. Gemcitabin/cisplatin (three or four cycli) was the regimen most used. Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer is scarcely utilized in the Netherlands.

bladder cancer, neoadjuvant chemotherapy, treatment, urothelial carcinoma
dx.doi.org/10.1007/s13629-014-0011-x, hdl.handle.net/1765/61665
Tijdschrift voor Urologie
Department of Urology

Boormans, J.L, Hans, M.G, & De Oliveira Barbosa, T.C. (2014). Neoadjuvante chemotherapie for muscle-invasive bladder cancer (urothelial carcinoma) in the Netherlands. Tijdschrift voor Urologie, 4(2), 50–56. doi:10.1007/s13629-014-0011-x